Singapore markets close in 1 hour 16 minutes

Zynex, Inc. (ZYXI)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
11.23-0.03 (-0.27%)
At close: 04:00PM EDT
11.23 0.00 (0.00%)
After hours: 04:00PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close11.26
Open11.36
Bid11.20 x 100
Ask11.27 x 200
Day's range11.18 - 11.53
52-week range6.88 - 14.75
Volume127,688
Avg. volume209,004
Market cap358.571M
Beta (5Y monthly)0.45
PE ratio (TTM)41.59
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend date05 Jan 2022
1y target estN/A
All
News
  • PR Newswire

    Zynex Sets First Quarter 2024 Earnings Call

    Zynex, Inc. (NASDAQ: ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, rehabilitation, and patient monitoring, will hold a conference call on Tuesday, April 30, 2024 at 4:15 PM Eastern Time to discuss its financial results for the first quarter ended March 31, 2024. Financial results will be issued in a press release prior to the call.

  • PR Newswire

    Zynex Earns Prestigious 2024 Top Workplaces USA Employer Recognition Award

    Zynex, Inc. (NASDAQ: ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, rehabilitation, and patient monitoring, today announced it is a recipient of the prestigious 2024 Top Workplaces USA award, featured in USA TODAY. This achievement underscores the organization's dedication to fostering a people-first workplace culture and prioritizing the employee experience.

  • PR Newswire

    Zynex Reports Fourth Quarter and Full Year 2023 Financial Results

    Zynex, Inc. (NASDAQ: ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, rehabilitation, and patient monitoring, today reported its financial and operational results for the fourth quarter and full year ended December 31, 2023 and its Board of Directors has approved an additional program to repurchase up to $20.0 million of the Company's common stock.